Skip to main content

Table 1 Goblet cell carcinoid outcomes by different chemotherapy regimens

From: Goblet cell carcinoid of the appendix – diagnostic challenges and treatment updates: a case report and review of the literature

Study Type of study N Stage Histology Treatment CR PFS Overall survival
Garin et al. [23] 2002 Case report 1 IV Adenocarcinoid 5-FU + LV (LV5FU2) × 1 cycle followed by FOLFOX 4 × 9 months Yes (at 8 months) 3 years
Pham et al. [11] 2006 Retrospective review 57 I – 8
II – 20
III – 6
IV – 23
Goblet cell carcinoid 5-FU + LV-based chemotherapy (N = 27, Stage II–IV) Cx versus No Cx
Stage II–III
Mean (months): 47 versus 32 months (p = 0.383)
5 year (%): 43 versus 56
Stage IV
Mean (months): 39 versus 29 (p = 0.281)
5 year (%): 26 versus 0
Toumpanakis et al. [24] 2007 Retrospective review 15 I–IV Goblet cell appendiceal carcinoid RH in all patients without metastasis.
Stage IV (3)
2- VP-16 + cisplatin
1–5-FU + cisplatin +streptozotocin.
11/15 no disease (median follow-up 30 months) Median 30 months follow up:
− 11 alive with no disease
– 1 alive with metastatic disease
– 3 died of metastatic disease (9–14 months)
Tang et al. [13] 2008 Retrospective review 63 I – 2
II – 18
III – 3
IV – 40
Tang group
A – 30
B – 26
C – 7
Goblet cell carcinoid FOLFOX
FOLFIRI
(33/63)
Stage III (2/3)
Group B (14/26)
Group A – 86%
Group B – 15%
Group C – 0%
DSS %
(Tang groups)
3 years
Group A – 100%
Group B – 85%
Group C – 17%
5 years
Group A – 100%
Group B – 36%
Group C – 0%
Bilen et al. [25] 2013 Case series 1 Metastatic Poorly differentiated adenocarcinoma arising from goblet cell carcinoid FOLFOX followed by CRS and HIPEC (mitomycin-C) pCR Disease free at 7 months
Clift et al. [22] 2018 Retrospective review 21 I – 1
II – 10
III – 5
IV – 5
Tang group
A – 8
B – 10
C – 3
Goblet cell carcinoid Appendectomy: 12 (completion RH: 8)
RH: 6
Other resections: 3
6 received adjuvant cx with CAPOX – 5 dead of disease, 1 alive with no disease
DFS:
1-year: 94.7%
3-year: 74.2%
5-year: 74.2%
Mean OS (1-, 3-, and 5-year OS)
80.3 months (79.4%, 60%, and 60%)
Group A: 73.1 months (85.7%, 85.7%, 51.4%)
Group B: 83.7 months (all 66.7%)
Group C: 28.5 months (66.7%, 66.7%, not reached)
  1. 5-FU 5-fluorouracil, CAPOX capecitabine/oxaliplatin, CR complete response, CRS cytoreductive surgery, Cx chemotherapy, DFS disease-free survival, DSS disease specific survival, FOLFIRI 5-FU/LV/irinotecan, FOLFOX 5-Fu/LV/oxaliplatin, HIPEC hyperthermic intraperitoneal chemotherapy, LV leucovorin, OS overall survival, pCR pathologic complete response, PFS progression-free survival, RH right hemicolectomy, VP-16 etoposide